| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0009 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | 0.18 | 0.001 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.084 | 0.004 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.004 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.08 | 0.004 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.086 | 0.006 |